chemogenetic gene therapies / CODA Biotherap - LARVOL DELTA

CODA Biotherapeutics' Chemogenetic Gene Therapy Platform Can Control Focal Seizures in vivo (PRNewswire) - "CODA Biotherapeutics, Inc...announced the presentation of preclinical data suggesting that the Company's chemogenetic gene therapy platform can control focal seizures in vivo. Collectively, the results showed efficacy of the CODA chemogenetic approach in controlling spontaneous seizures in a model system that replicates many features of human temporal lobe epilepsy."

Preclinical • CNS Disorders • Epilepsy